Morgan Stanley Reaffirms Equal Weight Rating for Ascendis Pharma A/S (NASDAQ:ASND)

Morgan Stanley restated their equal weight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) in a research report sent to investors on Monday morning, Benzinga reports. They currently have a $109.00 target price on the biotechnology company’s stock. Several other equities research analysts have also recently weighed in on the company. StockNews.com […]

Related Keywords

Wellington ,New Zealand General ,New Zealand ,Ascendis Pharma ,Wellington Management Group ,Ascendis Pharmaas Company Profile ,Goldman Sachs Group Inc ,T Rowe Price Investment Management Inc ,Cantor Fitzgerald ,Avoro Capital Advisors ,Morgan Stanley ,Franklin Resources Inc ,Free Report ,Moderate Buy ,Management Group ,Capital Advisors ,Rowe Price Investment Management ,Sachs Group ,Franklin Resources ,Get Free Report ,Transcon Growth Hormone ,Transcon Parathyroid Hormone ,Transconc Type ,Ascendis Pharmaa S ,Nasdaq Asnd ,Wasnd ,Medical ,Reiterated Rating ,